[E-Daily Reporter Kwon Oh Seok ] JETEMA Co.,Ltd.(216080)is set to raise a total of 30 billion won through the issuance of convertible bonds (CBs) and convertible preferred shares (CPS). JETEMA Co.,Ltd. announced on the 19th that it held a board of directors meeting and decided on this funding plan. (Photo courtesy of JETEMA Co.,Ltd.) This issuance will proceed under terms of a 0% interest rate and a 10% premium over the base share price, and the structure does not include a repricing clause that lowers the conversion price in the event of a decline in the stock price. The company emphasizes that, given the relatively favorable terms of the issuance, it has secured funds while minimizing dilution of existing shareholders’ stakes. The raised funds are scheduled to be used to repay short-term debt and enhance financial stability. At the same time, the company explained that it has secured the financial capacity to invest in future global market expansion and the commercialization of new products. Based on the funds secured, JETEMA Co.,Ltd. plans to accelerate its push into the global toxin market. In particular, in the Chinese market, the company has established a stable revenue base by signing a 10-year exclusive supply agreement worth approximately 550 billion won with its local partner, Huadong Aesthetics (ZUOYI BIO). The company completed Phase 3 clinical trials in China in May of this year and is currently undergoing the approval process with the National Medical Products Administration (NMPA). Commercialization is expected in the second half of 2027. The company is also simultaneously pursuing entry into the U.S. market. JETEMA Co.,Ltd. has completed a U.S. Phase 2 clinical trial and is expanding its global business footprint by forging partnerships in Thailand, Turkey, and other regions. JETEMA Co.,Ltd. official stated, “This funding round focused on improving our financial structure and laying the groundwork for expansion into the Chinese market,” adding, “We will continue to achieve sustainable growth through the successful launch of JETEMA DerToxin in the Chinese market and the expansion of our global business.”
ABLE C&C(078520)is establishing a subsidiary in the Netherlands to serve as the control tower for its European operations. Following the establishment of its UK subsidiary, the company is setting up a…
On the afternoon of the 18th, at the Vuori pop-up store in Seongsu-dong, Seongdong-gu, Seoul, a different scene unfolded as I passed through the first and second floors—where clothes were displayed—an…
As global Big Pharma companies embark on large-scale mergers and acquisitions (M&A) to overcome the patent cliff and growth limitations, there are increasing instances of Chinese biotech companies bei…
